Updates in the treatment of advanced stage melanoma

Ana Sofía Ayala-Cortés, Verónica Garza-Rodríguez, Jorge Ocampo-Candiani

Research output: Contribution to journalArticle

Abstract

© 2014, Academia Nacional de Medicina. All rights reserved. Melanoma has shown a greater increase in frequency as compared to other neoplasms, demonstrated by a 619[%] incidence increase in the USA from 1950 to the year 2000. Its treatment has always been a challenge, and once it has metastasized, there are no available curative regimens. In recent years considerable progress in the understanding of its pathophysiology and progression has been achieved; with the description of the genetic, molecular, and immunologic changes, new and specific drugs have been developed, with better response rates than conventional chemotherapy. Currently, a broad scope of therapeutic choices is available, although only eight are approved by the FDA. In the following literature review we present some of the better-known systemic treatment options for melanoma, from conventional chemotherapy, molecular (MAPK inhibitors) and immunomodulatory (interleukin-2, tumor necrosis factor alpha, cytotoxic T lymphocyte antigen-4 and programmed death-1 inhibitors) therapies, to miscellaneous options, among which are angiogenesis inhibitors, apoptosis modulators, vaccines, and radiotherapy.
Original languageEnglish
Pages (from-to)145-155
Number of pages11
JournalGaceta Medica de Mexico
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Fingerprint

Melanoma
CTLA-4 Antigen
Drug Therapy
Angiogenesis Inhibitors
Therapeutics
Molecular Biology
Radiotherapy
Vaccines
Tumor Necrosis Factor-alpha
Apoptosis
Incidence
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Ayala-Cortés, A. S., Garza-Rodríguez, V., & Ocampo-Candiani, J. (2014). Updates in the treatment of advanced stage melanoma. Gaceta Medica de Mexico, 145-155.
Ayala-Cortés, Ana Sofía ; Garza-Rodríguez, Verónica ; Ocampo-Candiani, Jorge. / Updates in the treatment of advanced stage melanoma. In: Gaceta Medica de Mexico. 2014 ; pp. 145-155.
@article{cbd1ef32faef4db7a3e8197f4d2aae55,
title = "Updates in the treatment of advanced stage melanoma",
abstract = "{\circledC} 2014, Academia Nacional de Medicina. All rights reserved. Melanoma has shown a greater increase in frequency as compared to other neoplasms, demonstrated by a 619[{\%}] incidence increase in the USA from 1950 to the year 2000. Its treatment has always been a challenge, and once it has metastasized, there are no available curative regimens. In recent years considerable progress in the understanding of its pathophysiology and progression has been achieved; with the description of the genetic, molecular, and immunologic changes, new and specific drugs have been developed, with better response rates than conventional chemotherapy. Currently, a broad scope of therapeutic choices is available, although only eight are approved by the FDA. In the following literature review we present some of the better-known systemic treatment options for melanoma, from conventional chemotherapy, molecular (MAPK inhibitors) and immunomodulatory (interleukin-2, tumor necrosis factor alpha, cytotoxic T lymphocyte antigen-4 and programmed death-1 inhibitors) therapies, to miscellaneous options, among which are angiogenesis inhibitors, apoptosis modulators, vaccines, and radiotherapy.",
author = "Ayala-Cort{\'e}s, {Ana Sof{\'i}a} and Ver{\'o}nica Garza-Rodr{\'i}guez and Jorge Ocampo-Candiani",
year = "2014",
month = "1",
day = "1",
language = "English",
pages = "145--155",
journal = "Gaceta Medica de Mexico",
issn = "0016-3813",
publisher = "Academia Nacional de Medicina",

}

Ayala-Cortés, AS, Garza-Rodríguez, V & Ocampo-Candiani, J 2014, 'Updates in the treatment of advanced stage melanoma', Gaceta Medica de Mexico, pp. 145-155.

Updates in the treatment of advanced stage melanoma. / Ayala-Cortés, Ana Sofía; Garza-Rodríguez, Verónica; Ocampo-Candiani, Jorge.

In: Gaceta Medica de Mexico, 01.01.2014, p. 145-155.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Updates in the treatment of advanced stage melanoma

AU - Ayala-Cortés, Ana Sofía

AU - Garza-Rodríguez, Verónica

AU - Ocampo-Candiani, Jorge

PY - 2014/1/1

Y1 - 2014/1/1

N2 - © 2014, Academia Nacional de Medicina. All rights reserved. Melanoma has shown a greater increase in frequency as compared to other neoplasms, demonstrated by a 619[%] incidence increase in the USA from 1950 to the year 2000. Its treatment has always been a challenge, and once it has metastasized, there are no available curative regimens. In recent years considerable progress in the understanding of its pathophysiology and progression has been achieved; with the description of the genetic, molecular, and immunologic changes, new and specific drugs have been developed, with better response rates than conventional chemotherapy. Currently, a broad scope of therapeutic choices is available, although only eight are approved by the FDA. In the following literature review we present some of the better-known systemic treatment options for melanoma, from conventional chemotherapy, molecular (MAPK inhibitors) and immunomodulatory (interleukin-2, tumor necrosis factor alpha, cytotoxic T lymphocyte antigen-4 and programmed death-1 inhibitors) therapies, to miscellaneous options, among which are angiogenesis inhibitors, apoptosis modulators, vaccines, and radiotherapy.

AB - © 2014, Academia Nacional de Medicina. All rights reserved. Melanoma has shown a greater increase in frequency as compared to other neoplasms, demonstrated by a 619[%] incidence increase in the USA from 1950 to the year 2000. Its treatment has always been a challenge, and once it has metastasized, there are no available curative regimens. In recent years considerable progress in the understanding of its pathophysiology and progression has been achieved; with the description of the genetic, molecular, and immunologic changes, new and specific drugs have been developed, with better response rates than conventional chemotherapy. Currently, a broad scope of therapeutic choices is available, although only eight are approved by the FDA. In the following literature review we present some of the better-known systemic treatment options for melanoma, from conventional chemotherapy, molecular (MAPK inhibitors) and immunomodulatory (interleukin-2, tumor necrosis factor alpha, cytotoxic T lymphocyte antigen-4 and programmed death-1 inhibitors) therapies, to miscellaneous options, among which are angiogenesis inhibitors, apoptosis modulators, vaccines, and radiotherapy.

M3 - Article

SP - 145

EP - 155

JO - Gaceta Medica de Mexico

JF - Gaceta Medica de Mexico

SN - 0016-3813

ER -

Ayala-Cortés AS, Garza-Rodríguez V, Ocampo-Candiani J. Updates in the treatment of advanced stage melanoma. Gaceta Medica de Mexico. 2014 Jan 1;145-155.